NEW YORK (GenomeWeb News) – Swift Biosciences today said it has completed a Series B financing round that raised $7 million.

Fletcher Spaght Ventures led the round and was joined by Renaissance Venture Capital Fund and Series A investors, including Mercury Fund, Michigan Accelerator Fund, and individuals.

"This funding will support the expansion of our sales and marketing programs, as well as accelerate new product introductions," Swift Bio's CEO David Olson said in a statement. "Our portfolio of creative, market-driven technologies continues to grow."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.